Black Friday Tomorrow: buy 2, get a 3rd free on every product Buy 2 = get a 3rd free, on every product Tomorrow: 3rd one free Buy 2 = 3rd one free Starts inEnds in Shop now
Free shipping on orders from 160 €from 160 € · 3-vial Retatrutide 30 mg pack at 150 € See the packs
MyPeptide Blog
Shop Quality Certificates Blog Contact About
Order
MyPeptide
Shop Quality Certificates Blog Contact About
ORDER
MyPeptide Blog
Home Shop Quality Blog Contact My account
Order
Skip to content
MyPeptide Logo - European Research Peptide Shop
  • Home
  • Shop
  • Quality
  • Blog
  • Contact
  • About
  • My account
MyPeptide Logo - European Research Peptide Shop
  • About — MyPeptide Research Team
  • Buy KPV in Luxembourg: price, COA Janoshik and delivery | MyPeptide.eu
  • Buy KPV in Belgium: price, COA Janoshik and delivery | MyPeptide.eu
  • Buy KPV in France: price, COA Janoshik and delivery | MyPeptide.eu
  • Buy retatrutide in Belgium: R3 Reta 10 mg at €59.90 | MyPeptide.eu
  • Buy GHK-Cu in Luxembourg: price, COA Janoshik and delivery | MyPeptide.eu
  • Buy GHK-Cu in Belgium: price, COA Janoshik and delivery | MyPeptide.eu
  • Buy GHK-Cu in France: price, COA Janoshik and delivery | MyPeptide.eu
  • Buy Research Peptides in Europe | MyPeptide.eu
  • Acquistare GHK-Cu in Italia: prezzo, COA Janoshik e consegna | MyPeptide.eu
  • Acquistare KPV in Italia: price, COA Janoshik and instructions | MyPeptide.eu
  • AHK-Cu hair: what studies say, AHK-Cu or GHK-Cu, price | MyPeptide.eu
  • Anti-Aging Peptides Europe — GHK-Cu, BPC-157 & More
  • Blog
  • Buy GHK-Cu in Ireland: Price, Janoshik COA and Delivery | MyPeptide.eu
  • Buy GHK-Cu in Malta: Price, Janoshik COA and Delivery | MyPeptide.eu
  • Buy KPV in Ireland: Price, Janoshik COA and Delivery | MyPeptide.eu
  • Buy KPV in Malta: Price, Janoshik COA and Delivery | MyPeptide.eu
  • Buy Peptides in Ireland: Supplier Guide, COA and Delivery | MyPeptide.eu
  • Buy Research Peptides in Europe
  • Buy Retatrutide in Ireland: Price, COA and Supplier | MyPeptide.eu
  • Buy Retatrutide in Malta: Price, COA and Supplier | MyPeptide.eu
  • Cagrilintide: what is it, mechanism, tests and status
  • Cagrilintide: side effects and safety
  • CagriSema: Trial results, tirzepatide and the FDA
  • Peptide calculator: reconstitution (mg/ml) and half-life | MyPeptide.eu
  • Certificates of analysis
  • COA of tesamorelin: Janoshik 98.2% analysis and verification | MyPeptide.eu
  • Cagrilintide COA: Janoshik report 99.836%
  • GHK-Cu COA: 3 Janoshik analyses, recognizing genuine GHK-Cu | MyPeptide.eu
  • KLOW COA: 4 peptides measured by Janoshik
  • KPV COA: Janoshik report 98.8%
  • MOTS-c COA: Janoshik 99.553% analysis and verification | MyPeptide.eu
  • COA retatrutide: 7 verifiable Janoshik certificates of analysis | MyPeptide.eu
  • How to verify a Janoshik Certificate of Analysis (COA) in 5 steps
  • Comprar Cagrilintide em Portugal
  • Comprar GHK-Cu en España: precio, COA Janoshik y envío | MyPeptide.eu
  • Buy KPV in Portugal: preço, COA Janoshik and purchase | MyPeptide.eu
  • Buy KPV in Spain: price, COA of Janoshik and envío | MyPeptide.eu
  • Buy Retatrutide in Portugal: preço desde 5 €/mg, COA Janoshik | MyPeptide.eu
  • Comprar Retatrutide en España: precio desde 5 €/mg, COA Janoshik | MyPeptide.eu
  • Comprar Tirzepatide em Portugal
  • Terms of Use
  • General Terms and Conditions of Sale – MyPeptide
  • Contact details – Legal notice
  • Cumpără GHK-Cu în România: preț, COA Janoshik și livrare | MyPeptide.eu
  • Cumpără KPV în România: preț, COA Janoshik și livrare | MyPeptide.eu
  • Cumpără Retatrutide în România: preț, COA și furnizor | MyPeptide.eu
  • Bacteriostatic water: uses, pharmacy, price and storage | MyPeptide.eu
  • FAQ – Frequently Asked Questions about Research Peptides
  • GHK-Cu: A Complete Guide to Copper Peptide (Research, Forms, Prices) | MyPeptide.eu
  • GHK-Cu hair: what studies say, GHK-Cu or AHK-Cu | MyPeptide.eu
  • Injectable or cream-based GHK-Cu: What forms, what are the differences? | MyPeptide.eu
  • GHK-Cu kaufen in Deutschland: Preis, Janoshik-COA & Versand | MyPeptide.eu
  • GHK-Cu kaufen in Österreich: Preis, Janoshik-COA und Zustellung | MyPeptide.eu
  • GHK-Cu kopen in Nederland: prijs, Janoshik-COA en levering | MyPeptide.eu
  • GHK-Cu kupić w Polsce: cena, certyfikat Janoshik i dostawa | MyPeptide.eu
  • GHK-Cu vásárlás Magyarországon: ár, Janoshik COA és szállítás | MyPeptide.eu
  • GLP-3: What is it? Retatrutide, a triple agonist (price, COA) | MyPeptide.eu
  • Complete Guide to NAD+: Longevity, Sirtuins, and DNA Repair
  • Complete Guide to Retatrutide: Mechanisms, Research and Clinical Results
  • Home
  • Kjøp GHK-Cu i Norge: pris, Janoshik-COA og levering | MyPeptide.eu
  • Kjøp retatrutide i Norge: pris, COA og leverandør | MyPeptide.eu
  • Kjøpe KPV i Norge: taken, Janoshik-COA and levering | MyPeptide.eu
  • KLOW: Side effects, risks and reviews
  • KLOW benefits: what studies really say
  • KLOW peptide: what is it, composition, studies and price
  • KLOW vs GLOW vs Wolverine: what are the differences?
  • Køb GHK-Cu i Danmark: pris, Janoshik-COA og levering | MyPeptide.eu
  • Køb retatrutide i Danmark: pris, COA og leverandør | MyPeptide.eu
  • Købe KPV i Danmark: taken, Janoshik-COA and levering | MyPeptide.eu
  • Köp GHK-Cu i Sverige: pris, Janoshik-COA och leverans | MyPeptide.eu
  • Köp retatrutide i Sverige: pris, COA och leverantör | MyPeptide.eu
  • Köpa KPV i Sverige: taken, Janoshik-COA och leverans | MyPeptide.eu
  • Koupit GHK-Cu v Česku: cena, COA Janoshik a doručení | MyPeptide.eu
  • Koupit KPV v Česku: cena, COA Janoshik a doručení | MyPeptide.eu
  • Koupit retatrutide v Česku: cena, COA a dodavatel | MyPeptide.eu
  • KPV: studied benefits for the gut and skin
  • KPV: What is it, how does it work, research, and its status?
  • KPV: Side effects, safety and status
  • KPV can be found in Germany: Prices, Janoshik-COA and Versand | MyPeptide.eu
  • KPV can be found in Österreich: Prices, Janoshik-COA and Delivery | MyPeptide.eu
  • KPV open in Nederland: prices, Janoshik-COA in leverage | MyPeptide.eu
  • Oral or injectable KPV: what the studies say
  • KPV or BPC-157: what are the differences?
  • KPV vásárlás Magyarországon: ár, Janoshik COA és szállítás | MyPeptide.eu
  • Kupić KPV w Polsce: cena, COA Janoshik i dostawa | MyPeptide.eu
  • Kúpiť GHK-Cu na Slovensku: cena, COA Janoshik a doručenie | MyPeptide.eu
  • Kúpiť KPV na Slovensku: cena, COA Janoshik a dručenie | MyPeptide.eu
  • Kúpiť retatrutide na Slovensku: cena, COA a dodávateľ | MyPeptide.eu
  • Kupiti GHK-Cu u Hrvatskoj: cijena, Janoshik COA i dostava | MyPeptide.eu
  • Kupiti KPV u Hrvatskoj: cijena, Janoshik COA i dostava | MyPeptide.eu
  • Kupiti Retatrutide u Hrvatskoj: cijena, COA i dobavljač | MyPeptide.eu
  • Mistä ostaa KPV:tä Suomessa? Hinta, Janoshik-COA ja toimitus | MyPeptide.eu
  • MOTS-c: What is it, effects, studies and price (complete guide) | MyPeptide.eu
  • MOTS-c: Side effects, dangers, and reviews (what we know) | MyPeptide.eu
  • MOTS-c and weight loss: metabolism, insulin, what the studies say | MyPeptide.eu
  • MOTS-c and sport: the peptide that "mimics exercise," what the research says | MyPeptide.eu
  • MOTS-c vs SS-31 (elamipretide): Two mitochondrial peptides compared | MyPeptide.eu
  • MyPeptide reviews: is it a legit site?
  • Wave to buy GHK-Cu in Portugal: preço, COA Janoshik and entrega | MyPeptide.eu
  • Osta GHK-Cu Suomesta: hinta, Janoshik-COA ja toimitus | MyPeptide.eu
  • Osta retatrutide Suomesta: hinta, COA ja toimittaja | MyPeptide.eu
  • Copper peptides: GHK-Cu, AHK-Cu, differences and uses | MyPeptide.eu
  • Pharmaceutical Grade Peptides Europe — HPLC 99%+
  • R3 shot, injection, or pen: the different forms of retatrutide | MyPeptide.eu
  • Pirkt GHK-Cu Latvijā: cena, Janoshik COA un piegāde | MyPeptide.eu
  • Pirkt KPV Latvijā: cena, Janoshik COA un piegāde | MyPeptide.eu
  • Pirkt Retatrutide Latvijā: cena, COA un piegādātājs | MyPeptide.eu
  • Pirkti GHK-Cu Lietuvoje: kaina, Janoshik COA ir pristatymas | MyPeptide.eu
  • Pirkti KPV Lietuvoje: kaina, Janoshik COA ir pristatymas | MyPeptide.eu
  • Pirkti Retatrutide Lietuvoje: kaina, COA ir tiekėjas | MyPeptide.eu
  • Shipping Policy
  • Privacy Policy – MyPeptide
  • Return and refund policy
  • GHK-Cu price in Europe: 13 sellers compared
  • Price of retatrutide (R3) in France: from €5/mg
  • R3 (retatrutide): Is it a medication? Pharmacy, prescription, tablet | MyPeptide.eu
  • Research Peptides Fast Shipping Europe — 2–5 Days
  • Retatrutide: legal status in Europe, country by country (2026)
  • Retatrutide France: supplier, prices from €5/mg, COA Janoshik | MyPeptide.eu
  • Retatrutide kaufen in Deutschland: Preis ab 5 €/mg, Janoshik-COA | MyPeptide.eu
  • Retatrutide kaufen in Österreich: Preis, COA und Anbieter | MyPeptide.eu
  • Retatrutide kopen in Nederland en België: prices, COA & leverage | MyPeptide.eu
  • Retatrutide kupić w Polsce: cena, COA i dostawca | MyPeptide.eu
  • Retatrutide Luxembourg: Price, Purchase & Reliable Supplier | MyPeptide.eu
  • Retatrutide prezzo e acquisto in Italia: da 5 €/mg, COA Janoshik | MyPeptide.eu
  • Retatrutide vásárlás Magyarországon: ár, COA és beszállító | MyPeptide.eu
  • Retatrutide vs. cagrilintide: Differences, mechanisms, and trials | MyPeptide.eu
  • Retatrutide vs tesamorelin: differences, targets, and studies | MyPeptide.eu
  • Tesamorelin: What is it, studies, status and price | MyPeptide.eu
  • Tesamorelin: Side effects, dangers, and reviews (clinical trials) | MyPeptide.eu
  • Tesamorelin and visceral (belly) fat: what the trials show | MyPeptide.eu
  • Tesamorelin and bodybuilding: what the research really says | MyPeptide.eu
  • Weight Loss Peptides Europe — Retatrutide & More
  • Αγορά GHK-Cu στην Ελλάδα: Τιμή, COA Janoshik και Παράδοση | MyPeptide.eu
  • Αγορά GHK-Cu στην Κύπρο: Τιμή, COA Janoshik και Παράδοση | MyPeptide.eu
  • Αγορά KPV στην Ελλάδα: Τιμή, COA Janoshik και Παράδοση | MyPeptide.eu
  • Αγορά KPV στην Κύπρο: Τιμή, COA Janoshik και Παράδοση | MyPeptide.eu
  • Αγορά Retatrutide στην Ελλάδα: Τιμή, COA και Προμηθευτής | MyPeptide.eu
  • Αγορά Retatrutide στην Κύπρο: Τιμή, COA και Προμηθευτής | MyPeptide.eu
  • Buy Research Peptides — Retatrutide, GHK-Cu, NAD+ | MyPeptide.eu
  • Cart
  • Quality
  • Checkout
  • Contact
  • My account
By Samayyy / November 15, 2026
Science
13-minute read
Updated on November 15, 2026

Eloralintide (LY3841136): Eli Lilly's amylin agonist

In short: Eloralintide (code LY3841136) is an amylin analog developed by Eli Lilly. It primarily activates the AMY1 amylin receptor and is administered subcutaneously once weekly in trials. In phase 2 (263 adults, 48 weeks, The Lancet(2025), the average weight loss has reached 20 % at the highest dose, compared to 0.4% under placebo. Eight phase 3 trials are underway or in preparation, and no marketing authorization exists to date.

-20%
Weight at 48 weeks (phase 2, 9 mg)
1×/week.
Subcutaneous injection
AMY1
Targeted receiver as a priority
8
Phase 3 trials (Nov. 2026)

What is eloralintide?

Eloralintide (international nonproprietary name; development code LY3841136) is an investigational peptide from Eli Lilly, the company behind tirzepatide and retatrutide. It is a synthetic analog of human amylin, a 37-amino-acid hormone that is released by the beta cells of the pancreas along with insulin after meals, and which plays a role in the satiety signal.

Native amylin is poorly suited to research: it readily forms unstable fibrils and has a short duration of action. Pramlintide, the first amylin analog, must be injected two to three times a day. Like Novo Nordisk's cagrilintide, eloralintide was designed to be stable and effective for a full week. Lilly is developing it for the treatment of obesity, both alone and in combination with tirzepatide.

🔬 Molecular Design

According to the Lilly team that developed it (Briere et al., 2025), eloralintide retains a chain of 37 amino acids, including 3 non-coding amino acids (positions 11, 15, and 22). The disulfide bridge of native amylin is replaced by a more chemically stable methylene thioacetal bridge. A 20-carbon fatty acid diacid, attached to lysine 26 by a link of two glutamic acid residues, allows it to bind to blood albumin: this is what prolongs its duration of action. After a single dose, its terminal half-life, measured in phase 1, ranges from 12.9 to 15.3 days. The complete sequence is not published.

Mechanism: Amylin, another pathway than GLP-1

Amylin receptors are assemblies: the calcitonin receptor (CTR) associated with one of the RAMP proteins, resulting in the AMY1, AMY2 and AMY3 receptors. Their activation, especially in the brainstem (area postrema) and hypothalamus, reduces food intake and slows gastric emptying.

ℹ️ Amylin and GLP-1: two distinct pathways

Eloralintide is not not It is a GLP-1 agonist. It acts on a different family of receptors than semaglutide, tirzepatide, or retatrutide. This is why Lilly is also studying it in combination with tirzepatide: the two mechanisms can be additive rather than overlapping.

What does "selective" mean?

Cagrilintide is an agonist non-selective It activates AMY1, AMY3, and the calcitonin receptor with comparable potency. Eloralintide, on the other hand, primarily activates AMY1. In human cells, it is approximately 12 times more powerful on AMY1 than on the calcitonin receptor, and 11 times more than on AMY3 (Briere et al., 2025).

In rats, eloralintide induced less conditioned food aversion than cagrilintide, with comparable fat mass loss and less lean mass loss. Lilly hypothesizes that this results in better gastrointestinal tolerance. The authors themselves note that no "useful" selectivity threshold has been established, and no clinical trial has directly compared the two molecules.

Published results: from phase 1 to phase 2

Phase 1, single dose: 48 healthy volunteers

In the first trial (NCT05295940), 48 healthy volunteers received a single injection of 0.04 to 12 mg, or a placebo. Four weeks later, weight had decreased by 2.5% after 4 mg and by 4.4% after 12 mg, compared to an increase of 0.6% with placebo. Of 16 adverse events, 15 were mild. The pharmacokinetic profile is consistent with once-weekly administration (Briere et al., 2025).

Phase 1, repeated doses for 12 weeks: 100 participants

One hundred overweight or obese individuals received one injection per week for 12 weeks, without a gradual increase in dose. Average weight loss ranged from 2.6% to 11.3% depending on the group. The most frequent side effects were decreased appetite (19%), headaches (12%), and fatigue (11%). Digestive disorders remained infrequent: diarrhea 10%, nausea 8%, vomiting 4% (Bhattachar et al., 2026).

Phase 2: 263 adults for 48 weeks

The phase 2 trial (NCT06230523), published in The Lancet In December 2025, a study included 263 adults from 46 US centers: obese (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related condition, and without type 2 diabetes. The mean age was 49 years, mean weight 109 kg, mean BMI 39.1, and 78% were women. Each group received one injection per week: a fixed dose, a dose-increasing dose, or a placebo.

Test group Average weight loss at 48 weeks Nausea Fatigue
Placebo -0.4% 14 % 12 %
1 mg -9% 11 % 0 %
3 mg -12% 13 % 13 %
6 mg -18% 64 % 29 %
9 mg -20% 33 % 43 %
6 → 9 mg -20% 54 % 46 %
3 → 9 mg -16% 25 % 21 %

Estimate of "efficacy," which assumes that participants followed the treatment. Source: Billings et al., The Lancet, 2025.

Weight loss increases with the dose. Nausea also increases, with large differences between groups: 64% in the group receiving 6 mg initially, compared to 25% in the group where the dose was increased gradually from 3 mg. Fatigue is another common side effect. The authors conclude that there was clinically significant weight loss and overall good tolerability.

With tirzepatide: EloraTZP (phase 2)

On September 30, 2026, Lilly published the results of a 48-week Phase 2 trial, presented at the European Association for Diabetes Society (EASD) congress, in 367 obese or overweight adults with type 2 diabetes. The strongest combination (eloralintide 9 mg and tirzepatide 15 mg) resulted in up to 23,3 % Weight loss was higher in the combined regimen, compared to 14.8% for tirzepatide 15 mg alone, with a decrease in HbA1c of up to 2.9 points versus 2.4. Discontinuations due to adverse effects ranged from 10.8% to 27% depending on the combination, compared to 2.9% with tirzepatide alone, primarily for gastrointestinal issues. As of November 15, 2026, these results are only available through the press release and the congress proceedings; no articles are indexed in PubMed.

Phase 3: the ENLIGHTEN and AMPLIFY programs

Lilly launched the phase 3 ENLIGHTEN program for eloralintide alone at the end of 2025, followed by AMPLIFY for the combination with tirzepatide. Here are the eight trials registered on ClinicalTrials.gov as of November 15, 2026:

Trial Study population Expected participants Status Main end estimated
ENLIGHTEN-1
NCT07321886
Obesity or overweight, without type 2 diabetes 1 980 Recruitment in progress March 2028
ENLIGHTEN-2
NCT07282600
Obesity or overweight with type 2 diabetes 1 035 Recruitment in progress January 2028
ENLIGHTEN-3
NCT07369011
Obstructive sleep apnea and obesity or overweight 800 Recruitment in progress March 2028
ENLIGHTEN-4
NCT07353931
Knee osteoarthritis pain and obesity or being overweight 900 Recruitment in progress March 2028
ENLIGHTEN-6
NCT07392190
Persistent obesity despite weekly incretin 900 Recruitment in progress June 2028
ENLIGHTEN-10
NCT07900633
Type 2 diabetes and high cardiovascular risk 3 000 Not yet open November 2029
AMPLIFY-1
NCT07881432
EloraTZP, obesity or overweight without type 2 diabetes 2 115 Not yet open October 2029
AMPLIFY-2
NCT07881458
EloraTZP, obesity or overweight with type 2 diabetes 1 000 Recruitment began on 16/10/2026 October 2029

The first phase 3 results are therefore not expected before 2028. Lilly is also testing eloralintide with another of its molecules, macupatide (LY3532226), in two phase 2 trials (NCT07215559 and NCT07589608).

Eloralintide vs cagrilintide, retatrutide and tirzepatide

The table places eloralintide among similar molecules. The figures come from different trials (populations, durations, methods): it is not a direct comparison.

Molecule Laboratory Targeted receptors Pace Reference published weight loss Stadium (Nov. 2026)
Eloralintide Eli Lilly Amylin (AMY1 preferred) Weekly −20% at 48 weeks. (phase 2, 9 mg) Phase 3 (ENLIGHTEN)
Cagrilintide Novo Nordisk Amylin and calcitonin (non-selective) Weekly −10.8% at 26 weeks. (phase 2, 4.5 mg) With semaglutide (CagriSema): application submitted to the FDA in December 2025
Retatrutide Eli Lilly GLP-1, GIP and glucagon Weekly −24.2% at 48 weeks. (phase 2, 12 mg) Phase 3 (TRIUMPH)
Tirzepatide Eli Lilly GLP-1 and GIP Weekly −20.9% at 72 weeks. (phase 3 SURMOUNT-1, 15 mg) Approved as a medicine

Over the same 48-week period, the phase 2 results for eloralintide alone (−20%) remained lower than those for retatrutide (−24.2%) in a different trial. Its advantage lies elsewhere: it uses a different mechanism of action than incretins, hence its study in combination (EloraTZP) and in individuals whose obesity persists despite incretin therapy (ENLIGHTEN-6). For the other amylin analog, see our comparison. retatrutide vs cagrilintide.

What we don't yet know

  • No results from phase 3. The published data relates to 148 people in phase 1 and 263 in phase 2.
  • The real contribution of selectivity. The digestive benefit has been shown in rats; in phase 2 trials, nausea affected up to 64% of one group. No trials directly compare eloralintide to cagrilintide.
  • The duration of the effect. Weight changes beyond 48 weeks, and after stopping treatment, are not published.
  • Type 2 diabetes. The published phase 2 excluded diabetic individuals; the only data in this population comes from the EloraTZP press release, pending ENLIGHTEN-2.
  • The complete structure. The exact sequence of the molecule is not published.

Eloralintide at MyPeptide

Eloralintide is not yet listed in the MyPeptide catalog. For amylin pathway research, Cagrilintide 5 mg is available with its verifiable Janoshik analysis report. For incretin agonists, see our retatrutide formulations.

Frequently Asked Questions about Eloralintide

What is eloralintide?

Eloralintide (code LY3841136) is an amylin analog developed by Eli Lilly. It primarily activates the AMY1 amylin receptor and is administered subcutaneously once weekly in clinical trials. It is in phase 3 clinical trials for the treatment of obesity, both alone and in combination with tirzepatide.

What weight loss has eloralintide shown?

In the phase 2 trial published in The Lancet (2025), the average weight loss at 48 weeks ranged from 9% in the 1 mg group to 20% in the 9 mg group, compared to 0.4% in the placebo group, in 263 adults without diabetes. These are clinical trial averages, not a guarantee of individual results.

What is the difference between eloralintide and cagrilintide?

Both are amylin analogs administered once weekly. Cagrilintide (Novo Nordisk) also activates the calcitonin receptor with comparable potency; eloralintide (Eli Lilly) primarily activates the AMY1 receptor, and its half-life, as measured in phase 1 trials, is approximately two weeks. No trials have directly compared them.

Eloralintide or retatrutide: what's the difference?

Retatrutide activates three receptors (GLP-1, GIP, and glucagon); eloralintide acts on a different family, the amylin receptors. In phase 2, over 48 weeks, retatrutide showed a 24.2% reduction and eloralintide a 20% reduction, in two separate trials that are not directly comparable.

Is eloralintide approved as a drug?

No. As of November 15, 2026, eloralintide has not been approved for marketing in any country. The phase 3 ENLIGHTEN trials are ongoing, and the first trials are expected to be completed in 2028, according to ClinicalTrials.gov.

What is EloraTZP?

EloraTZP is the combination of eloralintide and tirzepatide being studied by Lilly. In phase 2 trials, in 367 adults with type 2 diabetes, it resulted in up to 23.3% weight loss at 48 weeks, compared to 14.8% for tirzepatide alone, according to Lilly's press release of September 30, 2026. Two phase 3 trials, AMPLIFY-1 and AMPLIFY-2, have been launched.

What side effects have been reported?

Nausea and fatigue were the main side effects. In phase 2, nausea varied considerably between groups: 64% in the group receiving 6 mg initially, 25% in the group where the dose was gradually increased from 3 mg, and 14% in the placebo group. Fatigue affected up to 46% of one group.

Is there a dosage for eloralintide?

No. No dosage is validated outside of clinical trials. The doses mentioned in this article are the groups used in published trials, not a recommendation. MyPeptide does not provide dosage information: its products are intended exclusively for scientific research.

Key points to remember

  • Eloralintide (LY3841136) is an amylin analog from Eli Lilly, which preferentially activates the AMY1 receptor.
  • One injection per week in the trials, with a half-life of approximately two weeks
  • Phase 2: -20% weight loss at 48 weeks At best, nausea and fatigue are the most frequent side effects.
  • Combined with tirzepatide (EloraTZP): up to 23.3% in people with diabetes, according to Lilly's press release
  • Eight phase 3 trials (ENLIGHTEN, AMPLIFY), first results not expected before 2028; no marketing authorization yet
Read also
  • Cagrilintide: the amylin analogue that complements GLP-1
  • Retatrutide vs cagrilintide: differences, mechanisms and trials
  • Semaglutide vs Retatrutide vs Tirzepatide: a scientific comparison
  • Brenipatide (LY3537031): Lilly's other experimental peptide

Sources

  • Billings LK et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2 trial. Lancet. 2025 · PMID 41207310
  • Bhattachar S et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes Obes Metab. 2026 · PMID 41559929
  • Briere DA et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: from discovery to clinical proof of concept. Mol Metab. 2025 · PMID 41109426
  • Lau DCW et al. Once-weekly cagrilintide for weight management in people with overweight and obesity (phase 2). Lancet. 2021 · PMID 34798060
  • Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023 · PMID 37366315
  • Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022 · PMID 35658024
  • Eli Lilly, press release of September 30, 2026: Phase 2 results of EloraTZP (eloralintide and tirzepatide). investor.lilly.com
  • ClinicalTrials.gov registry: Phase 2 trial NCT06230523 and Phase 3 trials listed above. NCT06230523

Changelog: November 15, 2026, publication.

Warning : This article is provided for scientific informational purposes only. Eloralintide is an investigational molecule and is not approved as a medicine. The information presented is derived from public sources (publications, clinical trial registries, and company announcements) and does not constitute medical advice. All MyPeptide.eu products are intended exclusively for scientific laboratory research.

📦 Amylin research at MyPeptide

Cagrilintide 5 mg · All GLP peptides • Verifiable Janoshik analysis reports • Delivery in 2 to 5 business days in Europe

Previous

Brenipatide (LY3537031): Eli Lilly's Monthly Dual GIP/GLP-1 Agonist — Scientific Guide

Warning : The products offered on MyPeptide.eu are intended exclusively for scientific research in the laboratory.

© 2026 MyPeptide.eu — All rights reserved · Designed in Europe · GDPR compliant
Certificates of AnalysisIs MyPeptide legit?Terms & ConditionsPrivacy PolicyTerms of ServiceReturn & Refund PolicyShipping PolicyLegal Notice
100% secure paymentVisaApple PayGoogle Pay
FRENDEITESPTNLPLSV
Back to top